Which MS drug strategy works best for older adults? new study aims to find out
NCT ID NCT07313462
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This study looks at two ways to treat multiple sclerosis (MS) when it first appears after age 50. One approach starts with a moderate-strength drug and only switches to a stronger one if needed. The other starts with a strong drug right away. Researchers will compare how often relapses happen and what side effects occur, using data from 830 patients. The goal is to find out which strategy works better for this older age group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre d'Investigation Clinique - CHU de Strasbourg - France
RECRUITINGStrasbourg, 67091, France
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
disease-modifying therapies (moderate: teriflunomide, dimethyl fumarate, diroximel fumarate, glatiramer acetate, interferon beta, peginterferon; strong: fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)
What this could lead to
If successful, this study could help doctors choose the best first treatment for people diagnosed with MS after age 50, potentially reducing relapses and side effects.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be influenced by factors other than the treatment. It cannot prove cause and effect, only suggest patterns.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.